KalVista Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:4XC1 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
28 Mar 24	Sell€13,799,192	TCG Crossover Management, LLC	Company	1,355,014	€10.18
20 Feb 24	Buy€924,289	Frazier Life Sciences Management, LP	Company	65,573	€14.10
16 Feb 24	Sell€12,207,432	TCG Crossover Management, LLC	Company	877,125	€15.06
14 Feb 24	Sell€558,132	Christopher Yea	Individual	39,886	€13.99
14 Feb 24	Sell€394,202	Edward Feener	Individual	28,171	€13.99
14 Feb 24	Sell€816,585	Thomas Crockett	Individual	58,356	€13.99
14 Feb 24	Sell€571,691	Benjamin Palleiko	Individual	40,855	€13.99
08 Feb 24	Buy€1,168,523	VR Adviser, LLC	Company	86,048	€13.69
30 Jan 24	Buy€1,176,251	VR Adviser, LLC	Company	88,099	€13.35
25 Jan 24	Buy€82,574	VR Adviser, LLC	Company	7,030	€11.75
24 Jan 24	Buy€1,139,370	VR Adviser, LLC	Company	99,129	€11.52
19 Jan 24	Buy€1,655,492	VR Adviser, LLC	Company	143,605	€11.58
16 Jan 24	Buy€306,409	VR Adviser, LLC	Company	26,246	€11.69
10 Jan 24	Buy€1,575,047	VR Adviser, LLC	Company	137,700	€11.56
04 Jan 24	Buy€657,496	VR Adviser, LLC	Company	59,369	€11.13
29 Dec 23	Buy€5,849,474	VR Adviser, LLC	Company	519,017	€11.31
12 Dec 23	Buy€2,754,410	Frazier Life Sciences Management, LP	Company	343,435	€8.84

Insider Trading Volume

Insider Buying: 4XC1 insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 4XC1?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	3,482	0.00825%
Individual Insiders	586,456	1.39%
General Public	3,124,455	7.41%
VC/PE Firms	8,512,598	20.2%
Hedge Funds	8,969,350	21.3%
Institutions	20,991,955	49.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.5%.

Top Shareholders

Top 25 shareholders own 83.54% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
11.4%	VR Adviser, LLC	4,824,731	€48.5m	0%	2.96%
8.74%	Frazier Life Sciences Management, LP	3,687,867	€37.1m	1.81%	1.89%
8.15%	Tang Capital Management, LLC	3,440,345	€34.6m	0%	4.23%
6.74%	Adage Capital Management, L.P.	2,845,000	€28.6m	304%	0.06%
6.36%	Suvretta Capital Management, LLC	2,684,005	€27.0m	10.9%	1.26%
5.31%	BlackRock, Inc.	2,242,025	€22.5m	36.3%	no data
4.28%	Saturn V Capital Management LP	1,807,563	€18.2m	-0.15%	8.67%
4.22%	The Vanguard Group, Inc.	1,781,419	€17.9m	2.82%	no data
3.91%	Tavistock Life Sciences	1,650,000	€16.6m	0%	1.05%
3.47%	Capital Research and Management Company	1,464,606	€14.7m	0%	no data
2.76%	TCG Crossover Management, LLC	1,163,356	€11.7m	-65.7%	1.15%
2.56%	Jefferies Financial Group Inc.,Asset Management Arm	1,080,000	€10.9m	4.85%	0.22%
2.44%	Driehaus Capital Management LLC	1,028,568	€10.3m	-0.59%	0.08%
1.86%	Citadel Advisors LLC	783,698	€7.9m	-15.6%	0.01%
1.7%	Dimensional Fund Advisors LP	716,964	€7.2m	23%	no data
1.49%	Geode Capital Management, LLC	630,048	€6.3m	20.7%	no data
1.42%	Dafna Capital Management, LLC	601,032	€6.0m	-0.74%	1.57%
1.27%	State Street Global Advisors, Inc.	537,102	€5.4m	16.9%	no data
1%	StemPoint Capital LP	423,174	€4.3m	0%	1.31%
0.82%	Woodline Partners LP	346,863	€3.5m	0%	0.04%
0.77%	Northern Trust Global Investments	326,496	€3.3m	18.6%	no data
0.73%	Morgan Stanley, Investment Banking and Brokerage Investments	306,184	€3.1m	429%	no data
0.72%	Pivotal BioVenture Partners LLC	304,277	€3.1m	29.7%	1.35%
0.68%	Rosalind Advisors, Inc.	287,985	€2.9m	-4.01%	2.91%
0.67%	Citigroup Inc.,Banking and Securities Investments	281,909	€2.8m	1.8%	no data